SARS-CoV-2 antibodies in breastmilk after COVID-19 infection versus after COVID-19 vaccination
SARS-CoV-2 antibodies in breastmilk after COVID-19 infection versus after COVID-19 vaccination
This explainer is more than 90 days old. Some of the information might be out of date or no longer relevant. Browse our homepage for up to date content or request information about a specific topic from our team of scientists.
This article has been translated from its original language. Please reach out if you have any feedback on the translation.
A study published in JAMA Paediatrics looks at breastmilk antibody induction, persistence, and neutralizing capacity after SARS-CoV-2 infection vs after mRNA vaccination.
A study published in JAMA Paediatrics looks at breastmilk antibody induction, persistence, and neutralizing capacity after SARS-CoV-2 infection vs after mRNA vaccination.
Publication
Association of Human Milk Antibody Induction, Persistence, and Neutralizing Capacity With SARS-CoV-2 Infection vs mRNA Vaccination
Not peer-reviewed
Peer-reviewed
What our experts say
Context and background
Resources
Expert Comments:
Prof Richard Tedder
My concern with this extensive, useful and thought-provoking paper is that they have used an indirect assay which is simply not the assay format of choice for a non-blood analytes such as the fluid from the breast milk. Their proof of concept was an experiment to show the IgA such as one would find in fractionated maternal milk was detectable by their indirect immunoassay. What is not clear is the sensitivity overall and specificity overall of this approach. Nevertheless it is an interesting paper and their choice of determining antibody to the receptor binding domain is appropriate.
